Evidence map›Paper›PMID 41629541›Full record

ArticleEndocrine2026

Residual glucose metabolism and Long-Term clinical outcomes in multivessel coronary artery disease: A cohort study.

Aijun You, Mengshi Li, Jianhua Xue, Xi Chen, Qing Zhang, Tianyi Zhu, Liang Zheng, Li Zhang

Abstract read
PubMed Publisher
In one paragraph

Article in Endocrine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Aijun You *Clinical Research Unit, Shanghai Tongji Hospital, Tongji University School of Medicine, 200065, Shanghai, China.
Mengshi Li *Changhai Clinical Research Unit, Shanghai Changhai Hospital, Naval Medical University, 200433, Shanghai, China.
Jianhua Xue *Department of Science and Education, Shanghai Health and Medical Center, 214065, Jiangsu, China.
Xi ChenClinical Research Unit, Shanghai Tongji Hospital, Tongji University School of Medicine, 200065, Shanghai, China.
Qing ZhangClinical Research Unit, Shanghai Tongji Hospital, Tongji University School of Medicine, 200065, Shanghai, China.
Tianyi ZhuClinical Research Unit, Shanghai Tongji Hospital, Tongji University School of Medicine, 200065, Shanghai, China.
Liang ZhengResearch Center for Translational Medicine, Shanghai East hospital, Tongji University School of Medicine, 200120, Shanghai, China. zhengliang@tongji.edu.cn.
Li ZhangClinical Research Unit, Shanghai Tongji Hospital, Tongji University School of Medicine, 200065, Shanghai, China. trudyzhang@163.com.

Funding

The Clinical Research Plan of SHDC SHDC2023CRS035The Clinical Research Plan of SHDC SHDC2024CRX011The Shanghai Municipal Health Commission Planning 202240341
6 · The paper itself

Abstract

backgroundThe 2023 Guideline for the Management of Patients with Chronic Coronary Artery Disease (CAD) highlights that CAD remains the leading cause of morbidity and mortality, even in patients with well-controlled glycemia. This study aimed to investigate the impact of residual glucose metabolism, measured via hemoglobin glycation index (HGI), on long-term clinical outcomes of patients with multivessel CAD.

methods1718 patients with multivessel CAD from the Medicine, Angioplasty or Surgery Registry were included. The primary and secondary outcomes were all-cause mortality and major adverse cardiac and cerebrovascular events (MACCE) at 5 years after enrollment, respectively. Cox proportional hazards and modified Poisson regression models were used to explore associations between HGI and long-term clinical outcomes.

resultsDuring a median follow-up of 5.00 years, the all-cause mortality and incidence of MACCE were 7.68% and 24.74%, respectively. In fully adjusted models, low HGI significantly increased risks of all-cause mortality (HR=1.909, 95% CI: 1.061-3.565) and MACCE (PR=1.428, 95% CI: 1.077-1.894) compared with high HGI, and an inverse J-shaped nonlinear relationship between HGI and the risk of all-cause mortality. Furthermore, HbA1c control status moderated the association between HGI and all-cause mortality (P interaction < 0.010), reflecting linear negative relationship between HGI and all-cause mortality in patients with well-controlled glycemia and U-shaped relationship in those with sub-optimally controlled glycemia.

conclusionsHGI was significantly associated with long-term clinical outcomes in patients with multivessel CAD, independent of HbA1c, suggesting that enhanced monitoring of residual glucose metabolism might be beneficial in patients with multivessel CAD.

Indexed as

Blood GlucoseCoronary Artery DiseaseGlycated HemoglobinAgedCohort StudiesFemaleHumansMaleMiddle AgedBlood GlucoseGlycated HemoglobinAll-cause mortalityCoronary artery diseaseHemoglobin glycation indexMajor adverse cardiac and cerebrovascular events

Identifiers

PMID41629541

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.